ASXInvestor Presentation - Transforming Cancer Detection
other announcement
BDX
Pharmaceuticals, Biotechnology & Life Sciences
Bcal Diagnostics
- Short interest
- 0.00%
- −0.01 pp 30d
- as of 6 June 2025
- Reported shorts
- 304
- Shares on issue
- 365.968M
Bcal Diagnostics (BDX) News
Latest articles and price-sensitive announcements with AI sentiment classification.
BREASTESTplus 2 clinically validated
other announcement
BCAL Introduces Avantect Multi-Cancer Early Detection Test
other announcement
Letter to Shareholders re Annual General Meeting
other announcement
Notice of Annual General Meeting/Proxy Form
other announcement
Google NewsBcal Diagnostics (ASX:BDX) Shares Rise 14%, Avantect Test Access Expansion in Focus - Kalkine
Bcal Diagnostics (ASX:BDX) Shares Rise 14%, Avantect Test Access Expansion in Focus Kalkine
Clarification of BCAL's Position in Relation to GSS
other announcement
BCAL Seeks Board Change at Genetic Signatures
other announcement
Investor Presentation September 2026
other announcement
Meet The CEO FY 2026 Results Webinar 3 Sept 2026 at 1PM
other announcement
BCAL Takes Interest in Genetic Signatures to 18.46%
other announcement
Bcal Diagnostics (ASX:BDX) Slips to a New 52-Week Low - Kalkine
Bcal Diagnostics (ASX:BDX) Slips to a New 52-Week Low Kalkine
BCAL Diagnostics (ASX:BDX) Shares Fall as FY27 Funding and Cancer Test Expansion Take Focus - Kalkine
BCAL Diagnostics (ASX:BDX) Shares Fall as FY27 Funding and Cancer Test Expansion Take Focus Kalkine
BCAL Diagnostics Limited (ASX:BDX) Share Price Falls 5.08% as Stock Trades Within Daily Range - Kalkine
BCAL Diagnostics Limited (ASX:BDX) Share Price Falls 5.08% as Stock Trades Within Daily Range Kalkine
Bcal Diagnostics Ltd (ASX: BDX) Share Price Update: Stock Declines Slightly as Health Care Index Closes Lower - Kalkine
Bcal Diagnostics Ltd (ASX: BDX) Share Price Update: Stock Declines Slightly as Health Care Index Closes Lower Kalkine
Quarterly Activities/Appendix 4C Cash Flow Report
other announcement
Why Did BCAL Diagnostics Ltd (ASX: BDX) Jump 12.33%? - Kalkine
Why Did BCAL Diagnostics Ltd (ASX: BDX) Jump 12.33%? Kalkine
BCAL Develops New Blood Test for Breast Cancer Recurrence
other announcement
Validation Agreement Signed with Sonic USA, for Breastest V2
other announcement
KalkineBCAL Diagnostics Broadens Early Detection Reach Across Australia
Highlights Early cancer testing access expands across Australia Telehealth pathway supports broader patient reach New leadership phase strengthens commercial direction BCAL Diagnostics is expanding access to blood-based early cancer detection across Australia through GP referral integration, telehealth support, and broader healthcare infrastructure initiatives. Healthcare innovation continues to reshape preventive care across Australia, and BCAL Diagnostics Ltd (ASX:BDX) is strengthenin...
Small CapsBCAL Appoints Anne-Louise Arnett as Chief Executive Officer
other announcement
BCAL Submits MSAC Application for Avantect Pancreatic Test
other announcement
BCAL Diagnostics Expands Avantect Testing Across National Pathology Networks
Highlights Avantect tests now accessible through Sonic and Healius networks. National rollout supports early detection of pancreatic and ovarian cancers. Expansion integrates advanced genomic and epigenomic analysis. BCAL Diagnostics (BDX) extends Avantect test availability nationwide, enhancing early cancer detection through key pathology networks and advanced diagnostic tools. Expanding Access to Life-Saving Diagnostics BCAL Diagnostics (ASX:BDX) has accelerated the rollout of its Ava...
BCAL Accelerates Rollout of Avantect Early Detection Tests
other announcement
BCAL Webinar Review Half Year Results 18 February 11am AEDT
other announcement
Pancreatic and Ovarian Cancer Early Detection Blood Testing
other announcement